ENDP up +4.04% percent Today $ENDP High is at 69.7
Post# of 39311
Posted On: 11/18/2014 11:20:48 AM
ENDP up +4.04% percent Today $ENDP High is at 69.78 and the Low 67.14 with current volume of 514,637.
Recent News posted below.
Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/
ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News
Endo International (ENDP) Strong On High Relative Volume Today
at The Street - 1 hr 18 mins ago
Trade-Ideas LLC identified Endo International (ENDP) as a strong on high relative volume candidate
ENDP: 69.56 (+2.50)
Endo Pharmaceuticals Earnings Hindsight: Down 3.6% in Last 12 Days (ENDP)
Comtex SmarTrend(R) - Mon Nov 17, 3:15PM CST
12 days ago, on November 5th, 2014, Endo Pharmaceuticals (NASDAQ:ENDP) reported its earnings. Analysts, on average, expected earnings of $0.99 per share on sales of $723.3 million. Endo Pharmaceuticals actually reported earnings of $1.15 per share on sales of $763.9 million, beating EPS estimates by $0.16 and beating revenue estimates by $40.6 million. Shares of Endo Pharmaceuticals have slipped from $68.70 to $66.26, representing a loss of 3.6%, since the company reported earnings 12 days ago.
ENDP: 69.56 (+2.50)
After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 69.56 (+2.50)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 69.56 (+2.50), ACT: 261.20 (+13.26), JAZZ: 169.14 (-0.35), UNH: 98.43 (+1.96), CELG: 106.47 (+2.11), CELGZ: 3.18 (-0.03)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.56 (+2.50), LCI: 46.81 (+0.17), BCRX: 10.51 (+0.39), LJPC: 11.05 (+0.01)
Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 69.56 (+2.50), RDY: 56.33 (+0.24)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 212.00 (+2.80), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), ABBV: 65.72 (+0.68)
Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST
ENDP: 69.56 (+2.50)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 108.49 (+1.69), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), SHPG: 208.72 (+2.73), DNDN: 0.17 (+0.02), SNSS: 2.21 (-0.10), ABBV: 65.72 (+0.68), SNY: 48.22 (+0.68), MNKD: 6.48 (+0.22), XOMA: 4.06 (+0.08)
Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 69.56 (+2.50)
Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST
ENDP: 69.56 (+2.50)
Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST
ENDP: 69.56 (+2.50)
Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST
ENDP: 69.56 (+2.50)
Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.66 (+0.29), CSTE: 59.59 (+0.18), FSS: 15.44 (-0.10), HL: 2.51 (-0.03), BBEP: 15.11 (+0.10), RRD: 16.81 (-0.11), CNP: 24.47 (+0.09), INXN: 28.28 (unch), OGE: 36.93 (+0.24), MNTA: 10.90 (+0.30), GLDD: 7.19 (+0.12), AXAS: 3.93 (+0.02), MEMP: 16.32 (+0.20), PWE: 4.13 (-0.04), ROC: 79.10 (+0.02), SSYS: 105.40 (+1.24), DNR: 9.89 (-0.12), MVIS: 1.70 (+0.01), PWR: 33.32 (+0.15), COV: 97.65 (+3.04), SMG: 60.01 (+0.40), SEP: 56.82 (-0.28), CLH: 49.44 (-0.28), ATHM: 41.74 (-1.11), STWD: 23.57 (-0.03), BPI: 10.92 (+0.06), LVLT: 49.23 (+0.91), AVA: 34.22 (+0.43), MGA: 104.47 (+0.57), BSFT: 26.49 (-0.07), EE: 38.45 (+0.29), CTSH: 52.70 (-0.36), DAVE: 24.77 (+0.10), NRG: 31.97 (+0.29), CEQP: 8.64 (+0.24), ACT: 261.05 (+13.11), AWR: 34.54 (+0.14), DUK: 80.68 (+0.38), LAMR: 52.94 (+0.18), CCC: 20.88 (+0.02), HFC: 43.25 (+0.13), RTI: 23.59 (-0.02), CHK: 22.87 (-0.51), NUS: 39.46 (+1.18), NICE: 46.22 (-0.34), HRC: 45.49 (+0.30), ENDP: 69.56 (+2.50), SE: 38.47 (-0.01), CBB: 3.43 (+0.03), GTN: 10.06 (-0.03), ANSS: 80.50 (+0.77), RLGY: 43.17 (+0.35), ENB: 45.68 (+0.54), SBGI: 27.26 (-0.28), ARIA: 6.17 (+0.13), LPX: 14.80 (unch), RDC: 23.80 (-0.06), KELYA: 15.40 (+0.32)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.64 (-0.59), ENDP: 69.56 (+2.50), VRX: 141.23 (+4.50), PFE: 30.55 (+0.23)
Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT
ENDP: 69.56 (+2.50)
Recent News posted below.
Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/
ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News
Endo International (ENDP) Strong On High Relative Volume Today
at The Street - 1 hr 18 mins ago
Trade-Ideas LLC identified Endo International (ENDP) as a strong on high relative volume candidate
ENDP: 69.56 (+2.50)
Endo Pharmaceuticals Earnings Hindsight: Down 3.6% in Last 12 Days (ENDP)
Comtex SmarTrend(R) - Mon Nov 17, 3:15PM CST
12 days ago, on November 5th, 2014, Endo Pharmaceuticals (NASDAQ:ENDP) reported its earnings. Analysts, on average, expected earnings of $0.99 per share on sales of $723.3 million. Endo Pharmaceuticals actually reported earnings of $1.15 per share on sales of $763.9 million, beating EPS estimates by $0.16 and beating revenue estimates by $40.6 million. Shares of Endo Pharmaceuticals have slipped from $68.70 to $66.26, representing a loss of 3.6%, since the company reported earnings 12 days ago.
ENDP: 69.56 (+2.50)
After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 69.56 (+2.50)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 69.56 (+2.50), ACT: 261.20 (+13.26), JAZZ: 169.14 (-0.35), UNH: 98.43 (+1.96), CELG: 106.47 (+2.11), CELGZ: 3.18 (-0.03)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.56 (+2.50), LCI: 46.81 (+0.17), BCRX: 10.51 (+0.39), LJPC: 11.05 (+0.01)
Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 69.56 (+2.50), RDY: 56.33 (+0.24)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 212.00 (+2.80), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), ABBV: 65.72 (+0.68)
Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST
ENDP: 69.56 (+2.50)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 108.49 (+1.69), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), SHPG: 208.72 (+2.73), DNDN: 0.17 (+0.02), SNSS: 2.21 (-0.10), ABBV: 65.72 (+0.68), SNY: 48.22 (+0.68), MNKD: 6.48 (+0.22), XOMA: 4.06 (+0.08)
Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 69.56 (+2.50)
Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST
ENDP: 69.56 (+2.50)
Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST
ENDP: 69.56 (+2.50)
Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST
ENDP: 69.56 (+2.50)
Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST
MDLZ: 38.66 (+0.29), CSTE: 59.59 (+0.18), FSS: 15.44 (-0.10), HL: 2.51 (-0.03), BBEP: 15.11 (+0.10), RRD: 16.81 (-0.11), CNP: 24.47 (+0.09), INXN: 28.28 (unch), OGE: 36.93 (+0.24), MNTA: 10.90 (+0.30), GLDD: 7.19 (+0.12), AXAS: 3.93 (+0.02), MEMP: 16.32 (+0.20), PWE: 4.13 (-0.04), ROC: 79.10 (+0.02), SSYS: 105.40 (+1.24), DNR: 9.89 (-0.12), MVIS: 1.70 (+0.01), PWR: 33.32 (+0.15), COV: 97.65 (+3.04), SMG: 60.01 (+0.40), SEP: 56.82 (-0.28), CLH: 49.44 (-0.28), ATHM: 41.74 (-1.11), STWD: 23.57 (-0.03), BPI: 10.92 (+0.06), LVLT: 49.23 (+0.91), AVA: 34.22 (+0.43), MGA: 104.47 (+0.57), BSFT: 26.49 (-0.07), EE: 38.45 (+0.29), CTSH: 52.70 (-0.36), DAVE: 24.77 (+0.10), NRG: 31.97 (+0.29), CEQP: 8.64 (+0.24), ACT: 261.05 (+13.11), AWR: 34.54 (+0.14), DUK: 80.68 (+0.38), LAMR: 52.94 (+0.18), CCC: 20.88 (+0.02), HFC: 43.25 (+0.13), RTI: 23.59 (-0.02), CHK: 22.87 (-0.51), NUS: 39.46 (+1.18), NICE: 46.22 (-0.34), HRC: 45.49 (+0.30), ENDP: 69.56 (+2.50), SE: 38.47 (-0.01), CBB: 3.43 (+0.03), GTN: 10.06 (-0.03), ANSS: 80.50 (+0.77), RLGY: 43.17 (+0.35), ENB: 45.68 (+0.54), SBGI: 27.26 (-0.28), ARIA: 6.17 (+0.13), LPX: 14.80 (unch), RDC: 23.80 (-0.06), KELYA: 15.40 (+0.32)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.64 (-0.59), ENDP: 69.56 (+2.50), VRX: 141.23 (+4.50), PFE: 30.55 (+0.23)
Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT
ENDP: 69.56 (+2.50)
(0)
(0)